Identification of genetic mutations associated with attenuation and changes in tropism of Urabe mumps virus

Journal of Medical Virology

Volumn 81, Issue 1, 2009, Pages 130-138

  Shah, Dion ^a   Vidal, Silvia ^b   Link, Malen A ^c   Rubin, Steven A ^c   Wright, Kathryn E ^a,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Attenuation; Mumps virus; Mutations; Vaccine

Indexed keywords

GLUTAMIC ACID; HN PROTEIN; LYSINE; MUMPS VACCINE; LIVE VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC IDENTIFICATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; LEWIS RAT; MENINGITIS; MUMPS VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PAROTITIS; PLANT GROWTH; RAT; SEQUENCE ANALYSIS; VACCINATION; VIROGENESIS; VIRUS GENE; VIRUS ISOLATION; VIRUS VIRULENCE; AMINO ACID SUBSTITUTION; ANIMAL; DNA SEQUENCE; GENETICS; ISOLATION AND PURIFICATION; MISSENSE MUTATION; PATHOGENICITY; VIROLOGY; VIRULENCE; VIRUS MENINGITIS;

MUMPS VIRUS; RATTUS;

AMINO ACID SUBSTITUTION; ANIMALS; HN PROTEIN; HUMANS; MENINGITIS, VIRAL; MUMPS VACCINE; MUMPS VIRUS; MUTATION, MISSENSE; PAROTITIS; RATS; SEQUENCE ANALYSIS, DNA; VACCINES, ATTENUATED; VIRULENCE;

EID: 58149260920     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21381     Document Type: Article

References (54)

1. Afzal MA, Yates PJ, Minor PD. 1998. Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain. J Infect Dis 177:265-266.
2. Amexis G, Fineschi N, Chumakov K. 2001. Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain. Virology 287:234-241.
3. Bakshi SS, Cooper LZ. 1990. Rubella mumps vaccines. Pediatr Clin North Am 37:651-668.
4. Balraj V, Miller E. 1995. Complications of mumps vaccines. Rev Med Virol 5:219-227.
5. Bousse TL, Taylor G, Krishnamurthy S, Portner A, Samal SK, Takimoto T. 2004. Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein. J Virol 78:13351-13355.
6. Brown EG, Furesz J, Dimock K, Yarosh W, Contreras G. 1991. Nucleotide sequence analysis of the Urabe mumps vaccine strain that caused meningitis in vaccine recipients. Vaccine 9:840-842.
7. Brown EG, Dimock K, Wright KE. 1996. The Urabe AM9 vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease. J Infect Dis 174:619-622.
8. Carsillo T, Traylor Z, Choi C, Niewiesk S, Oglesbee M. 2006. hsp72, a host determinant of measles virus neurovirulence. J Virol 80:11031-11039.
9. Centers for Disease Control and Prevention (CDC). 2006. Brief Report: Update: Mumps activity - United States, January 1-October 7, 2006. MMWR 55:1152-1153.
10. Çevik B, Smallwood S, Moyer SA. 2007. Two N-terminal regions of the Sendai virus L RNA polymerase protein participate in oligomerization. Virology 363:189-197.
11. Clarke DK, Sidhu MS, Johnsons JE, Udem SA. 2000. Rescue of mumps virus from cDNA. J Virol 74:4831-4838.
12. Connor JH, McKenzie MO, Parks GD, Lyles DS. 2007. Antivrial activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 362:109-117.
13. Crennell S, Takimoto T, Portner A, Taylor G. 2000. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol 7:1068-1074.
14. Forsey T, Mawn JA, Yates PJ, Bentley ML, Minor PD. 1990. Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and dideoxynucleotide sequencing. J Gen Virol 71:987-990.
15. Fuerst TR, Niles EG, Studier FW, Moss B. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 83:8122-8126.
16. Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG. 1996. African green monkey kidney (Vero) cells provide an alternate host cell system for Influenza A and B viruses. J Virol 70:5519-5524.
17. Grdzelishvili VZ, Smallwood S, Tower D, Hall RL, Hunt DM, Moyer SA. 2006. Identification of a new region in the vesicular stomatitis virus L polymerase protein which is essential for mRNA capmethylation. Virology 350:394-405.
18. Holmes DE, Moyer SA. 2002. The phosphoprotein (P) binding site resides in the N terminus of the L polymerase subunit of Sendai virus. J Virol 76:3078-3083.
19. Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, Brown EG, Holtzman MJ, Brody SL. 2006. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol 80:7469-7480.
20. Ivancic J, Gulija TK, Forcic D, Baricevic M, Jug R, Mesko-Prejac M, Mazuran R. 2005. Genetic characterization of L-Zagreb mumps vaccine strain. Vir Res 109:95-105.
21. Keller MA, Parks GD. 2003. Positive- and negative-acting signals combine to determine differential RNA replication from the paramyxovirus simian virus 5 genomic and antigenomic promoters. Virology 306:347-358.
22. Kimura M, Kuno-Sakai H, Yamazaki S, Yamada A, Hishiyama M, Kamiya H, Ueda K, Murase T, Hirayama M, Oya A, Nozaki S, Murata R. 1996. Adverse events associated with MMR vaccines in Japan. Acta Paed Jap 38:205-211.
23. Kövamees J, Rydbeck R, Örvell C, Norrby E. 1990. Hemagglutinin-neuraminidase (HN) amino acid alterations in neutralization escape mutants of Kilham mumps virus. Vir Res 17:119-130.
24. Lemon K, Rima BK, McQuaid S, Allen IV, Duprex WP. 2007. The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence. J Virol 81:8293-8302.
25. Lin Y, Bright AC, Rothermel TA, He B. 2003. Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. J Virol 77:3371-3383.
26. Malik T, Sauder C, Wolbert C, Zhang C, Carbone KM, Rubin SA. 2007. A single nucleotide change in the mumps virus F gene affects virus fusogenicity in vitro and virulence in vivo. J Neurovirol 13:513-521.
27. Nussbaum O, Broder CC, Berger EA. 1994. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol 68:5411-5422.
28. Parks GD. 1994. Mapping of a region of the paramyxovirus L protein required for the formation of a stable complex with the viral phoshoprotein P. J Virol 68:4862-4872.
29. Plemper RK, Compans RW. 2003. Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol 77:4181-4190.
30. Poch O, Blumberg BM, Bougueleret L, Tordo N. 1990. Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: Theoretical assignment of functional domains. J Gen Virol 71:1153-1162.
31. Raha T, Pudi R, Das S, Shaila MS. 2004. Leader RNA of Rinderpest virus binds specifically with cellular La protein: A possible role in virus replication. Vir Res 104:101-109.
32. Reyes-Leyva J, BaZos R, Borraz-Arghello M, Santos-López G, Rosas N, Alvarado G, Herrera I, Vallejo V, Tapia-Ramírez J. 2007. Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein. Microb Infect 9:234-240.
33. Rosas-Murrieta N, Herrera-Camacho I, Vallejo-Ruiz V, Millan-Perez L, Cruz C, Tapia-Ramirex J, Santos-Lopez G, Reyes-Leyva J. 2007. Differential sensitivity to interferon influsences the replication and transcription of Urabe AM9mumps virus variants in nerve cells. Microb Infect 9:864-972.
34. Rubin SA, Pletnikov M, Taffs R, Snoy PJ, Kobasa D, Brown EG, Wright KE, Carbone KM. 2000. Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans. J Virol 74:5382-5384.
35. Rubin SA, Amexis G, Pletnikov M, Vandersanden J, Mauldin J, Sauder C, Malik T, Chumakov K, Carbone KM. 2003. Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype. J Virol 77:11616-11624.
36. Rubin SA, Afzal MA, Powell CL, Bentley ML, Auda GR, Taffs RE, Carbone KM. 2005. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: And international collaborative study. J Inf Dis 191:1123-1128.
37. Saito H, Takahashi Y, Harata S, Tanaka K, Sato H, Suto T, Yamada A, Yamazaki S, Morita M. 1998. Cloning and characterization of the genomic RNA sequence of the mumps virus strain associated with a high incidence of aseptic meningitis. Microbiol Immunol 42:133-137.
38. Santos-López G, Cruz C, Pazos N, Vallejo V, Reyes-Leyva J, Tapia-Ramírez J. 2006. Two clones obtained from Urabe AM9 mumps virus vaccine differ in their replicative efficiency in neuroblastoma cells. Microbes Infect 8:332-339.
39. Sauder CJ, Vandenburgh KM, Iskow RC, Malik T, Carbone KM, Rubin SA. 2006. Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 350:48-57.
40. Sidhu MS, Menonna JP, Cook SD, Dowling PC, Udem SA. 1993. Canine distemper virus L gene: Sequence and comparison with related viruses. Virology 193:50-65.
41. Tahara M, Takeda M, Yanagi Y. 2005. Contributions of matrix and large protein genes of themeasles virus Edmonstonstrain to growth in cultured cells as revealed by recombinant viruses. J Virol 79:15218-15225.
42. Takeuchi K, Tanabayashi K, Hishiyama M, Yamada A, Sugiura A. 1991. Variations of nucleotide sequences and transcription of the SH gene among mumps virus strains. Virology 181:364-366.
43. Takimoto T, Tayor GL, Connaris HC, Crennell SJ, Portner A. 2002. Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. J Virol 76:13028-13033.
44. Vasconcelos D, Cai XH, Oglesbee M. 1998. Constitutive overexpression of the major inducible 70 kDa heat shock protein mediates large plaque formation by measles virus. J Gen Virol 79:2239-2247.
45. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-349.
46. Vincent S, Tigaud I, Schneider H, Buchholz CJ, Yanagi Y, Gerlier D. 2002. Restriction of measles virus RNA synthesis by a mouse host cell line: Trans-complementation by polymerase components or a human cellular factor(s). J Virol 76:6121-6130.
47. Wilson RL, Fuentes SM, Wang P, Taddeo EC, Klatt A, Henderson AJ, He B. 2006. Function of small hydrophobic proteins of paramyxovirus. J Virol 80:1700-1709.
48. Wright KE. 2006. Mumps. In: Newton VE, Vallely PJ, editors. Infection and hearing impairment. West Sussex, England: John Wiley & Sons, Ltd. pp. 109-126.
49. Wright KE, Dimock K, Brown EG. 2000. Biological characteristics of genetic variants of Urabe AM9 mumps vaccine virus. Vir Res 67:49-57.
50. Yamada A, Takeuchi K, Tanabayashi K, Hishiyama M, Sugiura A. 1989. Sequence variation of the P gene among mumps virus strains. Virology 172:374-376.
51. Yamanishi K, Takahashi M, Kurimura T, Ueda S, Minekawa Y, Ogino T, Suzuki N, Gaga K, Okuno Y. 1970. Studies on live mumps virus vaccine. III. Evaluation of newly developed live mumps virus vaccine. Biken J 13:157-161.
52. Yamanishi K, Takahashi M, Ueda S, Minekawa Y, Ogino T, Suzuki N, Okuno Y. 1973. Studies on live mumps virus vaccine. V. Development of a new mumps vaccine 'AM9' by plaque cloning. Biken J 16:161-166.
53. Yates PJ, Afzal MA, Minor PD. 1996. Antigenic and genetic variation of the HN protein of mumps virus strains. J Gen Virol 77:2491-2497.
54. Zaitsev V, von Itzstein M, Groves D, Kiefel M, Takimoto T, Portner A, Taylor G. 2004. Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: Implications for fusion. J Virol 78:3733-3741.